Fate Therapeutics (FATE) Competitors $0.96 -0.01 (-0.76%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.02 (+2.22%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. PRTA, CRVS, ERAS, ITOS, SLDB, ATXS, NBTX, FULC, CGEM, and KMDAShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Prothena Corvus Pharmaceuticals Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Kamada Fate Therapeutics (NASDAQ:FATE) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Do analysts prefer FATE or PRTA? Fate Therapeutics presently has a consensus price target of $3.30, indicating a potential upside of 245.26%. Prothena has a consensus price target of $19.75, indicating a potential upside of 142.03%. Given Fate Therapeutics' higher possible upside, equities research analysts clearly believe Fate Therapeutics is more favorable than Prothena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility & risk, FATE or PRTA? Fate Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Do insiders & institutionals believe in FATE or PRTA? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is FATE or PRTA more profitable? Fate Therapeutics has a net margin of -2,025.05% compared to Prothena's net margin of -2,929.30%. Fate Therapeutics' return on equity of -50.95% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,025.05% -50.95% -36.76% Prothena -2,929.30%-62.17%-54.43% Does the media favor FATE or PRTA? In the previous week, Prothena had 8 more articles in the media than Fate Therapeutics. MarketBeat recorded 12 mentions for Prothena and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.36 beat Prothena's score of 0.99 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, FATE or PRTA? Prothena has higher revenue and earnings than Fate Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$8.47M13.01-$186.26M-$1.45-0.66Prothena$10.34M42.48-$122.31M-$5.64-1.45 SummaryFate Therapeutics beats Prothena on 9 of the 16 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.23M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.6621.3874.9226.41Price / Sales13.01243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book0.349.6413.256.28Net Income-$186.26M-$53.20M$3.29B$270.38M7 Day Performance-1.06%0.44%0.47%2.70%1 Month Performance-12.31%4.26%4.59%5.99%1 Year Performance-76.22%9.43%73.41%25.94% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.9803 of 5 stars$0.96-0.8%$3.30+245.3%-76.0%$110.23M$8.47M-0.66550Positive NewsPRTAProthena3.4347 of 5 stars$8.49-0.7%$19.75+132.6%-62.9%$460.25M$135.16M-1.51130Analyst RevisionCRVSCorvus Pharmaceuticals2.4547 of 5 stars$5.90-4.2%$15.00+154.2%+14.3%$459.01MN/A0.0030Positive NewsERASErasca2.3694 of 5 stars$1.55-3.7%$3.71+139.6%-47.5%$456.71MN/A0.00120Analyst DowngradeITOSiTeos Therapeutics3.4493 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences3.146 of 5 stars$5.13-6.7%$15.00+192.4%-32.0%$428.28M$8.09M0.00100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.8503 of 5 stars$7.43-1.2%$29.00+290.3%-33.3%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6362 of 5 stars$8.71+0.1%$8.00-8.2%+96.0%$417.11M$39.18M0.00100News CoverageUpcoming EarningsShort Interest ↑FULCFulcrum Therapeutics2.6176 of 5 stars$7.27-5.1%$7.57+4.1%+120.1%$414.34M$80M0.00100News CoveragePositive NewsShort Interest ↓CGEMCullinan Therapeutics2.1975 of 5 stars$6.84-2.1%$26.80+291.8%-63.6%$412.93MN/A0.0030Analyst ForecastKMDAKamada4.5476 of 5 stars$7.22+1.1%$13.00+80.1%+28.6%$410.59M$160.95M21.24360Short Interest ↓ Related Companies and Tools Related Companies Prothena Alternatives Corvus Pharmaceuticals Alternatives Erasca Alternatives iTeos Therapeutics Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Nanobiotix Alternatives Fulcrum Therapeutics Alternatives Cullinan Therapeutics Alternatives Kamada Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
